Kallikrein 9 Antikörper (C-Term)

Produktnummer ABIN3031531

Produktdetails anti-Kallikrein 9 Antikörper

Target: Kallikrein 9 (KLK9)

Bindungsspezifität: C-Term

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser Kallikrein 9 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB)

Aufreinigung: Antigen affinity

Immunogen: An amino acid sequence from the C-terminus of human Kallikrein 9 (SVCHYLDWIQEIMEN) was used as the immunogen for this Kallikrein 9 antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: The stated application concentrations are suggested starting amounts. Titration of the Kallikrein 9 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 0.5-1 μg/mL

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Lagerung: -20 °C

Informationen zur Lagerung: After reconstitution, the Kallikrein 9 antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Details zu Kallikrein 9

Target: Kallikrein 9 (KLK9)

Andere Bezeichnung: Kallikrein 9 (KLK9 Produkte)

Synonyme: KLK-L3 antikoerper, KLKL3 antikoerper, 1200016C12Rik antikoerper, AI324041 antikoerper, Klk9 antikoerper, Klks3 antikoerper, rGK-9 antikoerper, rK9 antikoerper, kallikrein related peptidase 9 antikoerper, kallikrein related-peptidase 9 antikoerper, kallikrein 1-related peptidase C9 antikoerper, KLK9 antikoerper, Klk9 antikoerper, Klk1c9 antikoerper

Hintergrund: Kallikrein-related peptidase 9, also known as KLK9 or KLK-L3, belongs to the kallikrein subgroup of serine proteases, which have diverse physiologic functions in many tissues. The KLK9 gene contains 5 coding exons and is mapped to 19q13.41. The gene is regulated by steroid hormones in a human breast cancer cell line. Yousef et al.(2001) performed a quantitative analysis of KLK9 expression in ovarian cancer. The results indicated that KLK9 is under steroid hormone regulation in ovarian and breast cancer cell lines. KLK9 is a potential independent favorable prognostic marker for early-stage, low-grade, optimally debulked ovarian cancer patients.

UniProt: Q9UKQ9

Pathways: Komplementsystem